Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma

PloS One
Lisa ZimmerDirk Schadendorf

Abstract

Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two phase III trials. As patients with UM were excluded in these studies, the Dermatologic Cooperative Oncology Group (DeCOG) conducted a phase II to assess the efficacy and safety of ipilimumab in patients with metastatic UM. We undertook a multicenter phase II study in patients with different subtypes of metastatic melanoma. Here we present data on patients with metastatic UM (pretreated and treatment-naïve) who received up to four cycles of ipilimumab administered at a dose of 3 mg/kg in 3 week intervals. Tumor assessments were conducted at baseline, weeks 12, 24, 36 and 48 according to RECIST 1.1 criteria. Adverse events (AEs), including immune-related AEs were graded according to National Cancer Institute Common Toxicity Criteria (CTC) v.4.0. Primary endpoint was the OS rate at 12 months. Forty five pretreated (85%) and eight treatment-naïve (15%) patients received at least one dose of ipilimumab. 1-year and 2-year OS rates were 22% and 7%, respectively. Median OS was 6.8 months (95% CI 3.7...Continue Reading

Associated Clinical Trials

References

Jun 5, 2003·British Journal of Cancer·S C EdmundsD P Kelsell
Dec 4, 2004·Melanoma Research·Hayley E SpendloveRichard S Houlston
Feb 26, 2008·Investigative Ophthalmology & Visual Science·Wanhua YangJerry Y Niederkorn
Dec 17, 2008·Nature·Catherine D Van RaamsdonkBoris C Bastian
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Apr 21, 2009·American Journal of Ophthalmology·James J AugsburgerAdeel H Shaikh
Aug 8, 2009·Clinical and Experimental Immunology·K S PeggsJ P Allison
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles M BalchVernon K Sondak
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Nov 16, 2010·Seminars in Oncology·Anna Maria Di GiacomoMichele Maio
Nov 19, 2010·The New England Journal of Medicine·Catherine D Van RaamsdonkBoris C Bastian
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Jun 28, 2011·Ophthalmology·Arun D SinghAllan K Topham
Aug 13, 2011·Cancer Immunology, Immunotherapy : CII·Riccardo DanielliMichele Maio
Nov 3, 2011·Future Oncology·Anna MinchomJames Larkin
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Dec 6, 2012·Melanoma Research·Muhammad Adnan KhattakJames Larkin
Apr 30, 2013·Melanoma Research·Francesco SpagnoloPaola Queirolo
May 2, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Klaus G GriewankDirk Schadendorf
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Jun 27, 2013·British Journal of Cancer·K G GriewankM Zeschnigk
Sep 27, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MaioP A Ascierto
Jan 10, 2014·Cancer Medicine·Kristina BuderMatthias Goebeler
Feb 11, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LeyvrazU Keilholz
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Jun 19, 2014·JAMA : the Journal of the American Medical Association·Richard D CarvajalGary K Schwartz
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Apr 18, 2015·Melanoma Research·Chun-Lan ChangYeun Mi Yim
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LeyvrazU Keilholz

❮ Previous
Next ❯

Citations

Jul 29, 2016·Oncoimmunology·Ioannis KarydisChristian H Ottensmeier
Dec 2, 2015·Journal of Translational Medicine·Paolo A AsciertoMagdalena Thurin
Mar 19, 2016·Cancer·Chandrani ChattopadhyaySapna P Patel
Mar 24, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Francesco SpagnoloPaola Queirolo
Apr 6, 2016·Future Oncology·Kimberly M KomatsubaraRichard D Carvajal
Jul 13, 2016·Expert Review of Anticancer Therapy·Pol Specenier
Dec 3, 2016·Acta Oncologica·M K van der KooijE Kapiteijn
Jan 24, 2017·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Ilan Ben-ShabatRoger Olofsson Bagge
Apr 12, 2017·The Lancet Oncology·Kimberly M Komatsubara, Richard D Carvajal
Jun 9, 2017·PloS One·Chelsea Place JohnsonScott E Woodman
Jan 9, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S CuzzubboA F Carpentier
Dec 16, 2016·Experimental and Molecular Pathology·Heidi V N Küsters-VandeveldeWilleke A M Blokx
Nov 30, 2016·International Ophthalmology Clinics·Mark P BreazzanoAnthony B Daniels
Jan 12, 2017·Cell Communication and Signaling : CCS·Kemal CatakovicRoland Geisberger
Jun 18, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Leisha A EmensFrancesco M Marincola
Jun 27, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Markus V HepptCarola Berking
Jun 24, 2017·Cancer Medicine·Carolin BenderJessica C Hassel
Jun 24, 2017·Pigment Cell & Melanoma Research·Pui Ying ChanPeter W Szlosarek
Mar 27, 2018·Cancer·Katy K TsaiSapna P Patel
Sep 23, 2018·Reviews in Endocrine & Metabolic Disorders·Silvia Martina FerrariAlessandro Antonelli
Mar 30, 2019·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·H Arzu YaşarYuksel Urun
Oct 28, 2015·British Journal of Cancer·Nabil Amirouchene-AngelozziSergio Roman-Roman
May 30, 2019·International Journal of Molecular Sciences·Silvia Martina FerrariAlessandro Antonelli
Jul 28, 2019·Cancers·Timo E Schank, Jessica C Hassel
Aug 31, 2016·The British Journal of Ophthalmology·Richard D CarvajalPaul D Nathan
Nov 17, 2019·International Journal of Molecular Sciences·Cristina Maria FaillaStefania D'Atri
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Kimberly M KomatsubaraAxel Hauschild
Oct 19, 2019·Cancers·Kalijn Fredrike BolInge Marie Svane
Aug 18, 2016·Journal for Immunotherapy of Cancer·Lucie HeinzerlingJason J Luke
Feb 6, 2020·International Journal of Molecular Sciences·Anja WesselyMarkus Vincent Heppt
Jul 6, 2019·Current Medicinal Chemistry·Snježana KaštelanKoraljka Hat
Mar 27, 2020·Journal for Immunotherapy of Cancer·Nicholas D KlemenMario Sznol
Dec 6, 2017·Current Opinion in Oncology·Vivian Chua, Andrew E Aplin
Jun 9, 2019·Cancer Immunology, Immunotherapy : CII·Ernesto RossiGiovanni Schinzari
Jun 14, 2020·Cancers·Lionel Larribère, Jochen Utikal

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01801358
NCT01377025
NCT01835145
NCT01587352
NCT01585194

Software Mentioned

SAS

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.